Inventory Of Fda-Approved Adc Drugs
The global ADC drug market will be approximately $5.2 billion by 2021
Apparatus
Apparatus
Watch Out For The Me Better 'Trap' Behind The Changing Future Of Frα Adc Rising Stars
The "me better" strategy has always been a great story for pharmaceutical companies.
Apparatus
Ovarian Cancer Heavyweight Cutting-Edge ADC Drug Elahere Proven Safe And Effective
On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.
Apparatus
Heavyweight! First ADC Drug Approved For Hormone Receptor-Positive Breast Cancer!
The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.
Apparatus
Study Confirms Widespread Presence Of Nectin-4 Target In Head And Neck Cancer, ADC Drug In Play!
Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).
Apparatus
Heavyweight! First ADC Drug For Refractory Ovarian Cancer Receives Accelerated FDA Approval
Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.